Academic literature on the topic 'TGFβ1 treatment'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'TGFβ1 treatment.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "TGFβ1 treatment"
Budhu, Sadna, Aditi Gupta, Kelly Fitzgerald, Rachel Giese, Adam Michel, Aliya Holland, Luis Felipe Campesato, et al. "567 Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of stroma poor cancers." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A596. http://dx.doi.org/10.1136/jitc-2021-sitc2021.567.
Full textBudhu, Sadna, Aditi Gupta, Rachel Giese, Jacques van Snick, Catherine Uyttenhove, Gerd Ritter, Jedd D. Wolchok, and Taha Merghoub. "Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer." Journal of Immunology 202, no. 1_Supplement (May 1, 2019): 136.23. http://dx.doi.org/10.4049/jimmunol.202.supp.136.23.
Full textShynlova, Oksana, Prudence Tsui, Anna Dorogin, B. Lowell Langille, and Stephen J. Lye. "The expression of transforming growth factor β in pregnant rat myometrium is hormone and stretch dependent." Reproduction 134, no. 3 (September 2007): 503–11. http://dx.doi.org/10.1530/rep-07-0004.
Full textQuintela, M., R. M. SeñarÍs, and C. Diéguez. "Transforming Growth Factor-βs Inhibit Somatostatin Messenger Ribonucleic Acid Levels and Somatostatin Secretion in Hypothalamic Cells in Culture*." Endocrinology 138, no. 10 (October 1, 1997): 4401–9. http://dx.doi.org/10.1210/endo.138.10.5467.
Full textVarricchio, Lilian, John Mascarenhas, Anna Rita Migliaccio, Maureen O'Connor-McCourt, Gilles Tremblay, Jean-François Denis, Camelia Iancu-Rubin, and Ronald Hoffman. "AVID200, a Potent Trap for TGF-β Ligands Inhibits TGF-β1 Signaling in Human Myelofibrosis." Blood 132, Supplement 1 (November 29, 2018): 1791. http://dx.doi.org/10.1182/blood-2018-99-116474.
Full textElsafadi, Mona, Muthurangan Manikandan, Sami Almalki, Mohammad Mobarak, Muhammad Atteya, Zafar Iqbal, Jamil Amjad Hashmi, et al. "TGFβ1-Induced Differentiation of Human Bone Marrow-Derived MSCs Is Mediated by Changes to the Actin Cytoskeleton." Stem Cells International 2018 (2018): 1–14. http://dx.doi.org/10.1155/2018/6913594.
Full textFeger, Martina, Ioana Alesutan, Tatsiana Castor, Sobuj Mia, Katharina Musculus, Jakob Voelkl, and Florian Lang. "Inhibitory Effect of NH4Cl Treatment on Renal Tgfß1 Signaling Following Unilateral Ureteral Obstruction." Cellular Physiology and Biochemistry 37, no. 3 (2015): 955–64. http://dx.doi.org/10.1159/000430222.
Full textRecouvreux, M. Victoria, M. Andrea Camilletti, Daniel B. Rifkin, and Graciela Díaz-Torga. "The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas." Journal of Endocrinology 228, no. 3 (December 23, 2015): R73—R83. http://dx.doi.org/10.1530/joe-15-0451.
Full textMartin, Constance J., Abhishek Datta, Christopher Littlefield, Ashish Kalra, Christopher Chapron, Stefan Wawersik, Kevin B. Dagbay, et al. "Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape." Science Translational Medicine 12, no. 536 (March 25, 2020): eaay8456. http://dx.doi.org/10.1126/scitranslmed.aay8456.
Full textPeng, Fangfang, Baifang Zhang, Dongcheng Wu, Alistair J. Ingram, Bo Gao, and Joan C. Krepinsky. "TGFβ-induced RhoA activation and fibronectin production in mesangial cells require caveolae." American Journal of Physiology-Renal Physiology 295, no. 1 (July 2008): F153—F164. http://dx.doi.org/10.1152/ajprenal.00419.2007.
Full textDissertations / Theses on the topic "TGFβ1 treatment"
Rautenbach, Robyn Marié. "Treatment-resistant ophthalmoplegia in Myasthenia gravis: extraocular muscle pathology, the role of TGFβ1 and the derivation of induced pluripotency towards 'disease-in-a-dish' modeling." Master's thesis, University of Cape Town, 2016. http://hdl.handle.net/11427/22782.
Full textAl, Maghout Tamer [Verfasser]. "P38 Kinase, SGK1 and NF-κB Dependent Up-Regulation of Na+/Ca2+ Exchanger Expression and Activity Following TGFß1 Treatment of Megakaryocytes / Tamer Al Maghout." Tübingen : Universitätsbibliothek Tübingen, 2020. http://d-nb.info/1221596780/34.
Full textHsu, Yi-Chao, and 許益超. "Effects of Salvia miltiorrhiza treatment on TGFβ-1 and procollagen gene transcripts in cirrhotic rats." Thesis, 2002. http://ndltd.ncl.edu.tw/handle/96153456417532675740.
Full text國立陽明大學
傳統醫藥學研究所
90
The Chinese herb, Salvia miltiorrhiza (Sm), has been shown to reduce hepatic fibrosis in rats. In this study, we investigated the effects of Sm in an experimental model of hepatic fibrosis and evaluated their effects on TGFb-1, procollagens I、III genes involved in hepatic fibrogenesis. Hepatic fibrosis was induced in male Sprague-Dawley rats (250~300 g) by common bile duct ligation (CBDL). Sham-operated (Sham) rats served as control. In part I of this study, the expression of TGFb-1, procollagens I、III mRNA was then investigated in the CBDL and Sham group at 1 day and 1, 2, 4, 6 weeks after CBDL. In part II study, effects of herbs on TGFb-1, procollagens I、III mRNA expressions in CBDL rats were investigated. The livers were analyzed by RT-PCR for the transcription of genes involved in liver fibrosis. The transcripts were normalized against that of G3PDH and analyzed statistically. There were two separate animal experimental protocols in part II study: (1) Sm crude extract study, and (2) Sm partially purified extract study. The active compound salvianolic acid B was about 80% in Study (2) and about 3%in Study (1). There were five groups in Sm crude extract study: Sham group, CBDL group, CBDL-silymarin (30 mg/kg), CBDL-low dose of Sm crude extract (30 mg/kg) and CBDL-high dose of Sm crude extract (100 mg/kg) for 4 weeks after bile duct ligation. There were six groups in Sm partially purified extract study: Sham group, Sham -high dose of Sm partially purified extract (100 mg/kg), CBDL group, CBDL-silymarin (100 mg/kg), CBDL-low dose of Sm partially purified (20 mg/kg) and CBDL-high dose of Sm partially purified extract (100 mg/kg) for 4 weeks after bile duct ligation. The results showed that TGFb-1 mRNA expression was induced in CBDL rats and procollagens I、III mRNA were up-regulated after CBDL. The results of animal experimental study showed that neither silymarin (30 mg/kg) nor Sm crude extract treatments could significantly reduce the expression of TGFb-1, procollagens I、III mRNA. On the other hand, we found that silymarin (100 mg/kg) and Sm partially purified extract could significantly reduce the expression of procollagens I、III mRNA, but had no effect on TGFb-1 mRNA expression at 4 weeks after CBDL. In conclusion, mRNA expression of TGFb-1, procollagens I、III was found increased in CBDL rats. We also found Sm crude extract and silymarin (30 mg/kg) could not reduce hepatic fibrosis in CBDL rats, and that Sm partially purified extract, which contained higher content of salvianolic acid B, and silymarin (100 mg/kg) could reduce procollagens mRNA expression and ameliorate hepatic fibrosis in CBDL rats.
Book chapters on the topic "TGFβ1 treatment"
Tortolina, Lorenzo, Nicoletta Castagnino, Cristina De Ambrosi, Annalisa Barla, Alessandro Verri, Gabriele Zoppoli, Luca Bagnasco, et al. "Dynamic Simulations of Pathways Downstream of TGFβ, Wnt and EGF-Family Growth Factors, in Colorectal Cancer, including Mutations and Treatments with Onco-Protein Inhibitors." In New Challenges for Cancer Systems Biomedicine, 127–42. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2571-4_7.
Full textWang, Yiting. "A novel theranostics nanoparticles pGGA-PTX / SPION with bifunction of diagnosis and treatment." In Is it all just an Akt - you’d be SMAD to believe it! Role of TGFβ1 in oral cancer metastasis. Science Repository Oü, 2018. http://dx.doi.org/10.31487/j.rdi.2018.10.06.
Full textKuznietsova, Halyna, and Olexandr Ogloblya. "Therapy that Targets Growth Factor Receptors: Novel Approach for Liver Cirrhosis Treatment." In Advances in Hepatology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96552.
Full textMehmood, Sarmad, Sajjad Haider, Muhammad Naeem, Raees Khan, Muhammad Faheem, Bushra Bano, Syeda Marriam Bakhtiar, et al. "Biomaterials in Gene Therapy for Soft and Hard Tissues." In Omics Technologies for Clinical Diagnosis and Gene Therapy: Medical Applications in Human Genetics, 190–213. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815079517122010015.
Full textConference papers on the topic "TGFβ1 treatment"
Melchionna, Roberta, Pierluigi Iapicca, Francesca Di Modugno, Paola Trono, Novella Gualtieri, Maria Grazia Diodoro, Marcella Mottolese, et al. "Abstract A60: The hMENA Splicing Program: An important regulator of TGFβ1-driven EMT and invasiveness in pancreatic cancer." In Abstracts: AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.panca2014-a60.
Full textDeCant, Brian, Daniel Principe, Elizabeth Wayne, Emman Mascarinas, Hidayatullah Munshi, Barbara Jung, and Paul Grippo. "Abstract A21: Stromal-derived TGFβ facilitates pancreatic cancer development via repression of T-cell mediated cytotoxicity." In Abstracts: AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.panca2014-a21.
Full textRana, Tapasi, Anwesa Chakrabarti, Michael Freeman, and Swati Biswas. "Abstract 2143: Anti-TGFβ antibody treatment rescues doxorubicin- mediated bone loss in preclinical osteolytic breast cancer metastasis models." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2143.
Full textMatsueda, Satoko, Kunle Odunsi, and Richard C. Koya. "Abstract B36: TGFβ blockade and epigenetic modulation for cancer treatment: Efficient breast cancer targeted therapy with TCR-T cell transfer." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 27-30, 2018; Miami Beach, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm18-b36.
Full textCarbone, Carmine, Anna Tamburrino, Geny Piro, Marco Zanotto, Maria Mihaela Mina, Silvia Zanini, Federico Boschi, Aldo Scarpa, Giampaolo Tortora, and Davide Melisi. "Abstract 3605: Combined inhibition of IL-1, CXCR1/2, and TGFβ signaling pathways modulates in vivo acquired resistance to anti-VEGF treatment." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3605.
Full textBandyopadhyay, Abhik, Joseph Agyin, Fernando Lopez-Casillas, Long Wang, Tanuka Biswas, and Lu-Zhe Sun. "Abstract 1753: Comparison between early versus delayed treatment of breast cancer induced osteolytic bone metastasis by TGFβ inhibitors in a murine model." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1753.
Full textDemaria, Sandra, Claire Vanpouille-Box, Rachael E. Hawtin, Christie Fanton, Andy Conroy, Erik Evensen, Neha Dixit, et al. "Abstract 4987: Role of the PD-1/PDL-1 pathway in resistance of patients with metastatic breast cancer to treatment with radiotherapy and TGFβ neutralization." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4987.
Full textXu, Weidong, Zhenwei Zhang, Theresa Guise, Charles B. Brendler, and Prem Seth. "Abstract 723: Liver-detargeted Ad5/48 chimaeric hexon based oncolytic adenovirus targeting TGFβ signaling: A safe and effective approach for the treatment of prostate cancer bone metastases." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-723.
Full textLoskutoff, D. J., J. Mimuro, and C. Hekman. "PLASMINOGEN ACTIVATOR INHIBITOR." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644763.
Full text